Results 221 to 230 of about 472,362 (405)

Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches

Developing World Bioethics, EarlyView.
ABSTRACT This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching ...
Ubaka Ogbogu, Lauren Albrecht
wiley   +1 more source

Practice Guidelines in Acute Pancreatitis

American Journal of Gastroenterology, 2006
P. Banks, M. Freeman
semanticscholar   +1 more source

Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study

Developmental Medicine &Child Neurology, EarlyView.
Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.70051 Abstract Aim To describe the real‐world effects of trofinetide in individuals with Rett syndrome (RTT) using the 18‐month follow‐up analysis of the LOTUS study. Method Caregivers of any patients who were prescribed trofinetide under routine clinical care were eligible to ...
Louise Cosand, Haya Mayman, Jenny Downs, Victor Abler   +3 more
wiley   +1 more source

Early-Onset Fibrocalculous Pancreatic Diabetes Associated With SPINK1 Variants In Trans: A Rare Genetic Case. [PDF]

Diabetes Care
Kostrzewska P, Kuca P, Łaz R, Maksymiuk-Kłos A, Witek P.   +4 more
europepmc   +1 more source

Acute pancreatitis complicating dengue hemorrhagic fever [PDF]

, 2016
K. Jagadish Kumar, Anitha Chandrashekar, Chetak Kadabasal Basavaraja, Halasahalli Chowdegowda Krishna Kumar   +3 more
openalex   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Beyond the Surface: Novel Therapy Approach for Pancreatitis in the Setting of CFTR Dysfunction. [PDF]

Case Rep Gastrointest Med
Wright BA, Hodapp E, Hornick DB, Peña TA.   +3 more
europepmc   +1 more source

Conservative therapy of severe acute pancreatitis is a safe option – results of a 15-year long-term follow-up cohort study

, 2023
Guido Alsfasser, E. Klar, Judith Feitl, Clemens Schafmayer   +3 more
openalex   +1 more source

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source

Global, regional, and national burden and future projections of pancreatitis: A Joinpoint, APC, and ARIMA modeling analysis. [PDF]

Clin Exp Med
Zhang B, Liu J, Bao N, Xue H, Feng H, Lu Z, Zhang D, Sun W, Shapaer T, Zhao Z, Shang D, Bao C, Chen Y.   +12 more
europepmc   +1 more source